Varian Medical Systems Inc

Varian Medical Systems — Q3 FY2018 Earnings Presentation

36 slides from Varian Medical Systems's earnings presentation, Jul 25, 2018

  1. Slide 1: Third Quarter Fiscal Year 2018

    J. Michael Bruff Senior Vice President, Investor Relations [email protected] July 25, 2018 Third Quarter Fiscal Year 2018

  2. Slide 2: Forward-Looking Statements

    This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1

  3. Slide 3: Long-Term Strategy

    Long - Term Strategy

  4. Slide 4: Global leader in radiation therapy

    Eclipse ™ Treatment planning system RapidPlan ™ Knowledge - based planning software Calypso ® Real - time tracking technology Edge ™ System Full - body radiosurgery platform Halcyon ™ Image - guided IMRT treatment platform TrueBeam ® /VitalBeam ™ Trilogy ® /Clinac ® /UNIQUE ™ Treatment procedures wi

  5. Slide 5: Long-term growth and value creation strategy

    Long - term growth and value creation strategy 5 Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology

  6. Slide 6: Expand addressable market to patient-centered care coordination

    Long - term growth and value creation strategy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions 6 Interventional oncology Surgical oncology Diagnostic imaging Radiation oncology Precision medicine Medical oncology Generate insights Call on all oncologists Aggregate data Dissem

  7. Slide 7: Growth priorities and strategic enablers

    Growth priorities and strategic enablers 7 We are here Global Leader in Radiation Therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Long - Term Growth and Value Creation Strategy Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Marke

  8. Slide 8: Growth priority: Strengthen our leadership in radiation therapy

    Global market leader with >50% share in radiation therapy, maintaining share in a 7% growth market Grew linac installed base by 4%; total installed base of 8,046 units R&D up 8% maintaining commitment to driving high - quality, organic innovation Orders Growth in the quarter ⁃ Oncology orders growth

  9. Slide 9: Growth priority: Extend global footprint

    ~45% of Halcyon orders in emerging markets, since May 2017 launch ⁃ ~90% of emerging market orders to date were for incremental units Expanding access in Taiwan, with the acquisition of Cooperative CL Enterprises (COOP), a leading local distributor of radiotherapy equipment ~55% international orders

  10. Slide 10: Growth priority: Expand addressable market

    10 Growth priority: Expand addressable market Velocity 4.0 launched with RapidSphere, a module for Y90 Selective Internal Radiation Therapy (SIRT) dosimetry analysis, extending Velocity to the interventional oncology market Eclipse MCO orders of nearly 320 licenses to date (4Q FY17 launch) Unique so

  11. Slide 11: 3Q FY 2018 Business Highlights

    3Q FY 2018 Business Highlights

  12. Slide 12: Business highlights timeline

    Varian launches Halcyon 2.0 with kilovoltage cone - beam CT imaging at ESTRO Calypso Anchored Beacon transponder for lung receives FDA 510k clearance First patient treated with Varian HyperArc high - definition radiotherapy Varian publishes 2017 Sustainability Report AUG OCT DEC JAN FEB MARCH 2018 V

  13. Slide 13: Financial highlights

    0% 5% 10% 15% 20% 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 +2 pts Y/Y Cash Flow from Operations ($M) $0 $50 $100 $150 $200 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 Non - GAAP Operating Earnings (% of Revenues) Financial highlights Operating Trends* Strong performance in key financial measures • Revenu

  14. Slide 14: Varian linac installed base

    Varian linac installed base Installed Base Trends Varian strengthened its global leadership in radiation therapy • Each geography grew respective installed base in the third quarter 14 Q3FY17 8,046 Total Q2FY18 7,766 Q4FY17 Q1FY18 Q3FY18 +4%

  15. Slide 15: Key wins

    Key wins Americas EMEA APAC Spain – Ortego Foundation, Catalunya 9 TrueBeams, 3 Halcyon systems Montefiore 1 TrueBeam, 1 Halcyon Unity Point 5 TrueBeam/Edge systems China – Chang Gung Memorial Hospital 1 Edge Australia – Peter MacCallum 4 TrueBeams Vietnam – VINMEC International Hospital TrueBeam or

  16. Slide 16: 3Q FY 2018 Financial Overview

    3Q FY 2018 Financial Overview

  17. Slide 17: Varian consolidated (GAAP) key P&L financial metrics

    Varian consolidated (GAAP) Key P&L Financial Metrics 17 • Gross orders of $767 million down 5%  Oncology orders +11% (+9% cc), with orders growth in the Americas and EMEA  No new ProBeam orders in the quarter; 4 orders in the trailing twelve months; pipeline remains strong • Revenues of $709 milli

  18. Slide 18: Varian consolidated (non-GAAP) key P&L financial metrics

    Varian consolidated (non - GAAP) Key P&L Financial Metrics 18 Note: Unless noted otherwise, all ‘Orders’ reflects Gross Orders, all growth rates are in dollars, and year on year, and all num bers reflect continuing operations. • Gross orders of $767 million down 5%  Oncology orders +11% (+9% cc), w

  19. Slide 19: Key balance sheet and cash flow metrics

    Varian consolidated Key Balance Sheet and Cash Flow Metrics • Cash Flow from Operations down 34%, due to a large cash receipt from Georgia Proton Treatment Center in prior year period  Trailing twelve - month cash flow from operations of $476 million  Oncology DSO down from 121 to 106 days • Conti

  20. Slide 20: Oncology operating segment key financial metrics

    Oncology operating segment Key Financial Metrics • Orders growth of 11% (+9% cc), with orders growth in the Americas and EMEA  Oncology orders mix: North America ~45%, International ~55%  17 new orders for Halcyon in the quarter • Product revenues growth of 29% driven by robust linac system sales,

  21. Slide 21: Oncology gross orders by geography

    21 Oncology gross orders by geography AMERICAS 9% 3Q Y/Y (+9% cc) 2% 3Q TTM 1 (+2% cc ) APAC - 7% 3Q Y/Y ( - 9% cc) - 3% 3Q TTM ( - 4% cc ) EMEA 27% 3Q Y/Y (+21% cc) 20% 3Q TTM (+14% cc ) (1) In North America, trailing twelve - month orders growth of 4% in dollars and constant currency

  22. Slide 22: Particle Therapy operating segment key financial metrics

    Particle Therapy operating segment Key Financial Metrics • No new orders for ProBeam systems in the quarter; 4 orders in the trailing twelve months; pipeline remains strong • 7 operational sites with 25 rooms in 5 countries; 16 more sites in progress across the world • Revenues, margins and related

  23. Slide 23: ProBeam proton therapy system sites

    ProBeam proton therapy system sites Operational Centers Centers Under Development 23 Treatment rooms ProBeam Sites Operational rooms Operational Sites 70 25 7 23

  24. Slide 24: FY 2018 Guidance

    FY 2018 Guidance var

  25. Slide 25: Updated Fiscal Year 2018 Guidance

    Varian consolidated Updated Fiscal Year 2018 Guidance 25 (1) These values are presented on a non - GAAP basis. We have not provided a reconciliation of non - GAAP guidance measures to the corresponding GAAP measures on a forward - looking basis due to potential significant variability and limited vi

  26. Slide 26: 3Q FY 2018 Financial Overview

    3Q FY 2018 Financial Overview

  27. Slide 27: Non-GAAP disclosure

    Non - GAAP disclosure 27 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted

  28. Slide 28: GAAP to non-GAAP reconciliation

    GAAP to non - GAAP reconciliation 28 (1) Includes $1.2 million, $1.3 million, $1.2 million, $1.5 million, and $1.9 million, respectively, in cost of revenues for the per iods presented. (2) Includes the hedging loss related to the Australian dollar purchase price for Sirtex Medical Limited amounting

  29. Slide 29: Total revenues by sales classification

    Total revenues by sales classification 29 CC – Constant currency $M 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 Product revenues $320.2 $399.7 $365.6 $393.8 $365.0 Y/Y 18% 8% 14% Service revenues $312.6 $322.1 $312.9 $336.1 $344.1 Y/Y 7% 13% 10% Total revenues $632.8 $721.8 $678.5 $729.9 $709.1 Y/Y 13%

  30. Slide 30: Total revenues by product type

    Total revenues by product type 30 CC – Constant currency $M 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 Y/Y Hardware $281.4 $352.5 $320.4 $341.7 $314.6 12% Oncology $214.9 $303.4 $293.1 $311.6 $276.5 29% Particle Therapy $66.5 $49.1 $27.3 $30.1 $38.1 -43% Software $110.4 $120.1 $115.1 $126.7 $125.1 13%

  31. Slide 31: Total revenues by region

    Total revenues by region 31 CC – Constant currency $M 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 Americas revenues $336.3 $368.6 $356.7 $340.2 $342.6 Y/Y 20% 0% 2% Y/Y – CC 20% -1% 2% EMEA revenues $169.5 $220.4 $193.0 $253.8 $229.7 Y/Y 5% 37% 35% Y/Y – CC -2% 23% 28% APAC revenues $127.0 $132.8 $128.8

  32. Slide 32: Total Oncology revenues by sales classification

    Total Oncology revenues by sales classification 32 CC – Constant currency $M 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 Product revenues $253.7 $350.6 $338.3 $363.7 $326.9 Y/Y 20% 9% 29% Y/Y – CC 18% 7% 26% Service revenues $310.7 $318.7 $311.1 $334.3 $340.3 Y/Y 8% 13% 10% Y/Y – CC 6% 11% 7% Total reve

  33. Slide 33: Total Oncology revenues by region

    Total Oncology revenues by region 33 CC – Constant currency $M 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 Americas revenues $286.9 $347.1 $337.4 $321.2 $323.2 Y/Y 16% -3% 13% Y/Y – CC 16% -3% 13% EMEA revenues $157.6 $196.9 $183.5 $241.2 $208.5 Y/Y 9% 44% 32% Y/Y – CC 2% 29% 24% APAC revenues $119.9 $1

  34. Slide 34: Total Particle Therapy revenues by sales classification

    Total Particle Therapy revenues by sales classification 34 $M 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 Product revenues $66.5 $49.1 $27.3 $30.1 $38.1 Y/Y 2% 0% -43% Service revenues $1.9 $3.4 $1.8 $1.8 $3.8 Y/Y -49% 61% 95% Total revenues $68.4 $52.5 $29.1 $31.9 $41.9 Y/Y -4% 2% -39% VPT revenues as

  35. Slide 35: Oncology gross orders by region

    Oncology gross orders by region 35 CC – Constant currency $M 3Q FY17 4Q FY17 1Q FY18 2Q FY18 3Q FY18 Americas orders $331.9 $479.0 $299.5 $341.4 $362.9 Y/Y 2% 2% 9% Y/Y – CC 2% 2% 9% EMEA orders $204.5 $315.4 $190.4 $199.3 $259.1 Y/Y 19% 11% 27% Y/Y – CC 13% 0% 21% APAC orders $151.3 $153.0 $130.0 $

  36. Slide 36: Our promise: People powering victories

    Our promise 36 People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer

Varian Medical Systems — Q3 FY2018 Earnings Presentation on 6ix